Study on Quality Risk Management in the Implementation of Phase I Clinical Trials

Hu Feifei, Zhang Ruoming, Zhang Xianglin

Chinese Pharmaceutical Affairs ›› 2019, Vol. 33 ›› Issue (11) : 1235-1245.

Chinese Pharmaceutical Affairs ›› 2019, Vol. 33 ›› Issue (11) : 1235-1245. DOI: 10.16153/j.1002-7777.2019.11.005
Quality Management

Study on Quality Risk Management in the Implementation of Phase I Clinical Trials

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2019, 33(11): 1235-1245 https://doi.org/10.16153/j.1002-7777.2019.11.005

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉